MedPath

The effect of betamethasone cream in preventing radiation skin reaction in head and neck cancers

Phase 3
Conditions
Health Condition 1: null- Patients getting Radical Radiotherapy in Head and Neck malignancies
Registration Number
CTRI/2017/04/008298
Lead Sponsor
Dr Shyama Prem S
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
150
Inclusion Criteria

Patients should be recieving radical RT,With ECOG 1&2

Exclusion Criteria

Previously irradiated,connective tissue disorder,allergy to cream

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
efficacy of 0.1% Topical Betamethasone cream in decreasing the proportion of patients with Grade 2,3,4 radiation dermatitis in Head and Neck malignanciesTimepoint: from start of radiotherapy to 2 weeks following completion
Secondary Outcome Measures
NameTimeMethod
To assess patientsâ?? skin related quality of life using EORTC QLQ-H&N 35 quality of life scores <br/ ><br>Timepoint: At start of treatment and completion of treatment;To assess toxicities of topical application of 0.1% Betamethasone cream. <br/ ><br>Timepoint: From start of radiotherapy to 2 weeks following completion;To evaluate 0.1% Topical Betamethasone cream as an interventional agent in Radiation dermatitis based on time to develop grade 2,3,4 dermatitis <br/ ><br> <br/ ><br>Timepoint: from start of radiotherapy to 2 weeks following completion
© Copyright 2025. All Rights Reserved by MedPath